Chemotherapy Induced Anemia - Pipeline Insights, 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Chemotherapy Induced Anemia - Pipeline Insights, 2017" drug pipelines to their offering.

Chemotherapy Induced Anemia - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Chemotherapy Induced Anemia. This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Chemotherapy Induced Anemia.

This report also assesses the Chemotherapy Induced Anemia therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope:

  • The report provides competitive pipeline landscape of Chemotherapy Induced Anemia
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Chemotherapy Induced Anemia pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Chemotherapy Induced Anemia and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Chemotherapy Induced Anemia Overview
  2. Chemotherapy Induced Anemia Pipeline Therapeutics
  3. Chemotherapy Induced Anemia Therapeutics under Development by Companies
  4. Chemotherapy Induced Anemia Filed and Phase III Products
  5. Chemotherapy Induced Anemia Phase II Products
  6. Chemotherapy Induced Anemia Phase I and IND Filed Products
  7. Chemotherapy Induced Anemia Discovery and Pre-Clinical Stage Products
  8. Drug Candidate Profiles
  9. Chemotherapy Induced Anemia - Therapeutics Assessment
  10. Companies Involved in Therapeutics Development for Chemotherapy Induced Anemia
  11. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/zbjzhz/chemotherapy

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs